Jim Porter
CEO of Nuvalent
Best podcasts with Jim Porter
Ranked by the Snipd community
Oct 25, 2023 • 58min
Episode 77
Biotech analysts Jacob Plieth and Madeleine Armstrong, along with Nuvalent CEO Jim Porter, discuss Merck and Daichii's co-development deal, Nuvalent's $300M raise, and recent industry data. They also touch on the recent ESMO data breach, PTC Therapeutics' agreement with Royalty Pharma, and Revolution Medicines' KRAS data, among other topics.
